Sigrid Therapeutics is a Swedish clinical biotechnology company developing innovative solutions to prevent and treat lifestyle-related diseases. The company was founded in 2014 by Prof. Tore Bengtsson and Sana Alajmovic with the vision to change the way we manage modern chronic diseases. Their technology, SiPore®, consists of precision-engineered mesoporous silica particles that act in the gut to improve blood sugar control in a safe and effective way. The lead product, SiPore21®, is an oral medical device in clinical development, intended to improve metabolic function in people with prediabetes and new-onset type 2 diabetes. Sigrid Therapeutics is headquartered in Stockholm and is part of Karolinska Innovation's incubator program for promising life science startups in Sweden.
Sigrid Therapeutics has developed SiPore, a technology based on microscopic silica particles. The product works locally in the gut to reduce the absorption of fats and carbohydrates, which can contribute to more stable blood sugar levels and support weight management. SiPore targets both the consumer market and clinical applications.
Sigrid Therapeutics develops and commercializes products based on the SiPore technology. Its revenue model is centered around the sale of dietary supplements and medical foods, with plans for future licensing of the technology to third parties in the healthcare sector. The target audience includes both end consumers and professional users.
Sigrid Therapeutics has conducted clinical trials to assess the efficacy and safety of its products. SiPore is registered for marketing in the United States, and the company plans further geographic expansion. In parallel, ongoing development efforts aim to explore additional applications of the technology in adjacent therapeutic areas.
How it works in 6 simple steps:
How it works in 6 simple steps:
.avif)
.png)
